North America: Expanding mature ecosystem of biotech
North America is further segmented into the US and Canada. North America benefits from strong venture capital investments, a mature ecosystem of biotech startups, and early regulatory guidance for microbiome diagnostics. North America benefits from strong venture capital investments, a mature ecosystem of biotech startups, and early regulatory guidance for microbiome diagnostics.
Inflammatory bowel disease (IBD) is a group of lifelong diseases affecting the intestines, primarily including ulcerative colitis and Crohn's disease. In the United States, IBD affects an estimated 2.4 to 3.1 million adults, with prevalence rising overall.
Rates are highest among non-Hispanic White populations (0.8%) but are increasing among minority groups, and prevalence rises with age, particularly in adults over 45. Market data confirms that microbiome tests are being developed and used to assess disease risk including for IBD and to guide personalized interventions, expanding demand for gut microbiome analysis.
- According to CDC, inflammatory bowel disease affects approximately 2.4–3.1 million adults in the United States, significantly increasing demand for gut microbiome testing solutions. This growing disease burden supports expansion of precision diagnostics and clinical microbiome applications across healthcare systems.
Europe: Strong Production high health literacy
Europe is further segmented into Germany, France, UK, Italy, Spain, Russia, and Rest of the Europe. European consumers generally have high health literacy and awareness of the role of gut health in overall well-being. This, combined with strong public investment in digital health and diagnostic innovation, has expanded the market for both clinical microbiome testing and at home testing solutions.
The UK, Germany, and France major European markets show increasing uptake of gut microbiome tests, both for medical insight and broader wellness tracking. Estimated 0.3% of the European population suffers from IBD. Physicians and consumers are increasingly interested in gut microbiome tests to inform IBS, metabolic syndrome, and other chronic disease management, and to guide lifestyle interventions like diet or nutrition adjustments.
- ECDC reports that inflammatory bowel disease affects about 0.3% of the European population, highlighting rising diagnostic needs across hospitals and laboratories. This supports growth in microbiome-based testing for early detection, disease monitoring, and personalized healthcare interventions.
Asia Pacific: Fastest Growing rising health awareness
Asia-Pacific is further segmented into the China, India, Japan, South Korea, Malaysia, Thailand, Indonesia, and Rest of Asia-Pacific. The Asia Pacific market is rapidly expanding, supported by large populations, rising health awareness, and increasing prevalence of gastrointestinal disorders. IBS alone affects approximately 6%–10% of the regional population, implying hundreds of millions of potential patients across China, Japan, South Korea, and Southeast Asia, which drives demand for microbiome profiling.
Key regional players include AMILI (Singapore), SpaceGut (Malaysia), Metagen (Japan/Indonesia), Biota Health, and infrastructure leaders like BGI Group (China), offering both clinical and direct-to-consumer testing solutions. Apart from inflammatory bowel disease, metabolic disorders such as Type 2 diabetes, obesity, and non-alcoholic fatty liver disease (NAFLD) are major drivers of gut microbiome testing in Asia Pacific.
South America: Growing metabolic diseases
South America, high and rising rates of metabolic diseases are creating strong demand for gut microbiome testing because scientific evidence shows that alterations in the gut microbiome are mechanistically linked with obesity, type 2 diabetes (T2DM), and metabolic dysfunction associated fatty liver disease (MAFLD), all of which influence energy regulation, inflammation, and insulin sensitivity.
Metabolic syndrome and obesity are widespread across the region . South America has some of the highest MAFLD prevalence globally, substantially higher than many other regions, and risk factors such as dyslipidemia, hypertension, and T2DM are common in affected populations, creating a substantial comorbidity burden that correlates with gut microbiota changes relevant for testing and stratification.
Middle East & Africa: Emerging lifestyle changes
Middle East and Africa are further segmented into GCC Countries, South Africa, and Rest of Middle East and Africa. The Gulf Cooperation Council (GCC) countries Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates are experiencing a significant health crisis driven by high rates of chronic metabolic conditions, largely due to rapid urbanization, lifestyle changes, and sedentary behavior. Metabolic syndrome, a cluster of conditions including obesity, high blood pressure, and high blood sugar, affects most of the population in these countries, with rates rising.
The Kingdom's National Biotechnology Strategy aims to position Saudi Arabia as a leading regional biotech hub by 2030 and a global hub by 2040. This strategy is projected to contribute significantly to the non-oil GDP and create jobs by 2030. In 2024, the Saudi government launched the National Biotechnology Strategy, which aims to enhance the country's biotechnology capabilities.
In Africa, research initiatives supported by national foundations and international partners are laying groundwork for microbiome understanding in public health contexts such as infectious disease, malnutrition, and metabolic illness. Although still nascent, centers like the African Centre of Excellence for Genomics of Infectious Diseases (ACEGID) demonstrate the region’s growing genomics research infrastructure.
